Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.63 |
| ▸ | F10 | P00742 | 7/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223816 | 0.91 | NR1H4 (0.65) | NR1H4F10TP53NPC1RAB9A | |
| SCHEMBL5222102 | 0.88 | NR1H4 (0.64) | NR1H4F10TP53NPC1RAB9A | |
| SCHEMBL5225715 | 0.84 | F10 (0.76) | NR1H4F10TP53NPC1RAB9A | |
| SCHEMBL5223218 | 0.84 | NR1H4 (0.73) | NR1H4F10TP53NPC1RAB9A | |
| SCHEMBL5222845 | 0.83 | MAPT (0.63) | NR1H4F10TP53NPC1RAB9A | |
| SCHEMBL5228240 | 0.83 | NR1H4 (0.62) | NR1H4F10TP53NPC1RAB9A | |
| SCHEMBL7304276 | 0.83 | NPC1 (0.81) | NR1H4TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7301192 | 0.83 | NPC1 (0.81) | NR1H4TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5225091 | 0.81 | F10 (0.61) | NR1H4F10TP53NPC1RAB9A | |
| SCHEMBL5225151 | 0.81 | F10 (0.61) | NR1H4F10TP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-6596884-B2 | Synthesizing an analog of anthraquinone that is soluble in or miscible with carbon dioxide; reacting with hydrogen in carbon dioxide to produce tetrahydroquinone; reacting with oxygen to produce hydrogen peroxide; regenerating analog | UNIVERSITY OF PITTSBURGH | 2003-07-22 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-20020110516-A1 | Synthesis of hydrogen peroxide | NATIONAL SCIENCE FOUNDATION | 2002-08-15 | — | — | US | disclosed |
| US-6342196-B2 | COMPRISES SYNTHESIZING ANALOG OF ANTHRAQUINONE SOLUBLE IN OR MISCIBLE WITH CARBON DIOXIDE, REACTING ANALOG WITH HYDROGEN PRODUCES TETRAHYDROQUINONE, REACTING WITH OXYGEN REGENERATES ANTHRAQUINONE AND PRODUCES HYDROGEN PEROXIDE; SOLVENT-FREE | UNIVERSITY OF PITTSBURGH | 2002-01-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| US-20010007045-A1 | SYNTHESIS OF HYDROGEN PEROXIDE | NATIONAL SCIENCE FOUNDATION | 2001-07-05 | — | — | US | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000000428-A1 | SYNTHESIS OF HYDROGEN PEROXIDE | UNIVERSITY OF PITTSBURGH (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | NR1H4 2304/4885F10 12/4885TP53 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.